Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) insider Robert A. Lenz sold 5,563 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Neumora Therapeutics Stock Performance
NMRA stock traded up $0.11 during midday trading on Friday, hitting $15.51. 1,069,912 shares of the company’s stock were exchanged, compared to its average volume of 650,216. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00. The company has a market cap of $2.48 billion and a PE ratio of -6.06. The stock’s fifty day moving average price is $12.20 and its 200-day moving average price is $11.24.
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). On average, analysts expect that Neumora Therapeutics, Inc. will post -1.48 EPS for the current year.
Analyst Ratings Changes
Get Our Latest Research Report on Neumora Therapeutics
Institutional Investors Weigh In On Neumora Therapeutics
Several large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD acquired a new position in Neumora Therapeutics in the 1st quarter worth $10,354,000. Callan Capital LLC boosted its position in shares of Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after buying an additional 456,207 shares during the period. Rhumbline Advisers boosted its position in shares of Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock worth $1,015,000 after buying an additional 85,706 shares during the period. SG Americas Securities LLC acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at approximately $566,000. Finally, Marshall Wace LLP bought a new stake in Neumora Therapeutics in the 2nd quarter valued at approximately $1,323,000. Institutional investors own 47.65% of the company’s stock.
About Neumora Therapeutics
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
See Also
- Five stocks we like better than Neumora Therapeutics
- 5 discounted opportunities for dividend growth investors
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What Are Dividend Achievers? An Introduction
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.